Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Activating Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05258279
What this trial is testing

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Who this might be right for
Non-squamous Non-small-cell Lung CancerEGFR Activating Mutation
Juntendo University 30
Testing effectiveness (Phase 2)Study completedNCT01562028
What this trial is testing

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Who this might be right for
Lung Cancer
ETOP IBCSG Partners Foundation 109
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)UnknownNCT03267654
What this trial is testing

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 100
Not applicableUnknownNCT04944069
What this trial is testing

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Who this might be right for
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 69
Testing effectiveness (Phase 2)Study completedNCT02616393
What this trial is testing

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Who this might be right for
Non-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases
Kadmon Corporation, LLC 36
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88
Testing effectiveness (Phase 2)Ended earlyNCT02580708
What this trial is testing

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 7
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)WithdrawnNCT03042013
What this trial is testing

Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Who this might be right for
Subjects With NSCLC With an EGFR Activating Mutation
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Study completedNCT01667562
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 375
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Looking for participantsNCT07755397
What this trial is testing

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

Who this might be right for
NSCLC Patients With EGFR Activating MutationAdenoid Cystic Carcinoma MetastaticAdenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited 30
Large-scale testing (Phase 3)Study completedNCT01121393
What this trial is testing

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 364
Not applicableStudy completedNCT02293733
What this trial is testing

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
NSCLC Non Small Cells Lung Cancer
Groupe Francais De Pneumo-Cancerologie 144
Post-approval studies (Phase 4)Study completedNCT04511533
What this trial is testing

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Pfizer 101
Next Page